Literature DB >> 23410194

Intestinal mucormycosis: a rare entity in pediatric oncology.

Nita Radhakrishnan1, Satya Prakash Yadav, Jaswinder Oberoi, Rajeev Kulshreshta, Sunita Bhalla, Anupam Sachdeva.   

Abstract

Mucormycosis is increasingly emerging as an important cause of invasive fungal infection in immunocompromised patients. Intestinal mucormycosis is extremely rare, difficult to diagnose, and has dismal prognosis. We report two children with acute lymphoblastic leukemia and intestinal mucormycosis. Despite surgery and appropriate antifungal therapy, only one survived. Literature review showed only 10 other childhood cancer cases with intestinal mucormycosis. All had abdominal pain preceding gut perforation. All except one had leukemia and majority were in induction phase of therapy. Only 5 of these 12 children survived. Other than appropriate antifungal therapy, early surgery and rising neutrophils aid in recovery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410194     DOI: 10.3109/08880018.2013.769286

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  4 in total

1.  Novel therapeutic use of Versajet for intestinal mucormycosis.

Authors:  William Calvert; Dhanya Mullassery; Rajeev Shukla; Graham Lamont
Journal:  BMJ Case Rep       Date:  2014-03-03

Review 2.  Gastrointestinal and liver infections in children undergoing antineoplastic chemotherapy in the years 2000.

Authors:  Elio Castagnola; Eliana Ruberto; Alfredo Guarino
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 3.  Fungal infections of the gastrointestinal tract in the immunocompromised host: an update.

Authors:  Laura W Lamps; Keith K T Lai; Danny A Milner
Journal:  Adv Anat Pathol       Date:  2014-07       Impact factor: 3.875

4.  Esophageal mucormycosis in an immunocompetent child: A rare presentation.

Authors:  Jenna Blah Bhattacharya; Seema Kaushal; Satish Kumar Aggarwal
Journal:  Biomed J       Date:  2016-06-20       Impact factor: 4.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.